Redx Pharma Ltd
Redx is a clinical-stage biotechnology company dedicated to discovering and developing innovative, targeted medicines for fibrotic diseases, cancer, and related conditions. The company emphasizes high standards, agility, innovation, resilience, and teamwork to create differentiated treatments. Its pipeline includes programs targeting fibrosis and oncology, with a focus on GI-restricted ROCK inhibitors and porcupine inhibitors. Redx's research is published in scientific journals, and it actively participates in conferences and presentations. The company is committed to creating world-leading medicines to transform patients' lives.
Industries
Nr. of Employees
medium (51-250)
Redx Pharma Ltd
Redx Pharma Limited, Block 33 Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom
Patents
N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway
US-12202826-B2
View DetailsN-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
US-11643408-B2
View Details
N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway
US-12202826-B2
View DetailsN-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
US-11643408-B2
View DetailsProducts
Gastrointestinal‑restricted pan‑ROCK small‑molecule inhibitor (clinical‑stage)
Orally administered, gastrointestinal‑restricted pan‑ROCK inhibitor in clinical development for fibrostenotic gastrointestinal disease; progressed through Phase 1 healthy volunteer evaluation and prepared for Phase 2.
Selective ROCK2 small‑molecule inhibitor (clinical‑stage)
Orally available selective ROCK2 inhibitor under clinical development for idiopathic pulmonary fibrosis, interstitial lung disease and other fibrotic indications.
Wnt pathway small‑molecule inhibitor (clinical‑stage)
Orally active inhibitor of Wnt ligand secretion under clinical evaluation for ligand‑dependent tumours; studied as monotherapy and in combination with immune checkpoint inhibitors.
Selective DDR1 small‑molecule inhibitor (discovery/IND‑enabling)
Selective DDR1 inhibitor programme advanced through discovery towards IND‑enabling studies for treatment of kidney fibrosis and other chronic fibrotic diseases.
Circulating tumour DNA (ctDNA) assay (development/validation)
Development of a circulating tumour DNA assay to support genetically defined patient selection and screening for clinical trials.
Flow cytometry‑based immune cell analysis validation
Validated whole‑blood flow cytometry methods for immune cell analysis to support clinical biomarker studies.
Gastrointestinal‑restricted pan‑ROCK small‑molecule inhibitor (clinical‑stage)
Orally administered, gastrointestinal‑restricted pan‑ROCK inhibitor in clinical development for fibrostenotic gastrointestinal disease; progressed through Phase 1 healthy volunteer evaluation and prepared for Phase 2.
Selective ROCK2 small‑molecule inhibitor (clinical‑stage)
Orally available selective ROCK2 inhibitor under clinical development for idiopathic pulmonary fibrosis, interstitial lung disease and other fibrotic indications.
Wnt pathway small‑molecule inhibitor (clinical‑stage)
Orally active inhibitor of Wnt ligand secretion under clinical evaluation for ligand‑dependent tumours; studied as monotherapy and in combination with immune checkpoint inhibitors.
Selective DDR1 small‑molecule inhibitor (discovery/IND‑enabling)
Selective DDR1 inhibitor programme advanced through discovery towards IND‑enabling studies for treatment of kidney fibrosis and other chronic fibrotic diseases.
Circulating tumour DNA (ctDNA) assay (development/validation)
Development of a circulating tumour DNA assay to support genetically defined patient selection and screening for clinical trials.
Flow cytometry‑based immune cell analysis validation
Validated whole‑blood flow cytometry methods for immune cell analysis to support clinical biomarker studies.
Services
Engagement in partnering, licensing or co‑development arrangements to advance discovery- or clinical‑stage assets through development and commercialisation.
Engagement in partnering, licensing or co‑development arrangements to advance discovery- or clinical‑stage assets through development and commercialisation.
Expertise Areas
- Medicinal chemistry and computational drug design
- Translational pharmacology
- Small‑molecule targeted drug discovery (including kinase inhibitors)
- Target selection and validation
Key Technologies
- Medicinal chemistry
- Computational drug design (in silico modelling)
- Translational pharmacology assays
- Small‑molecule kinase inhibitor development